Kevin Harrington, Professor in Biological Cancer Therapies at the Institute of Cancer Research, shared a post on LinkedIn:
“I am very happy to share a short summary from the VJ Oncology of the data that I recently presented, on behalf of co-investigators, at ESMO 2025 in Berlin. These data from OrigAMI-4, cohort 1 demonstrate tolerability and remarkable efficacy of amivantamab in patients with HPV-negative, relapsed/metastatic head and neck cancer that has previously been treated with both platin-based chemotherapy and immune checkpoint blockade.
OrigAMI-4 has already delivered data that have resulted in the design of a phase III trial (OrigAMI-5) of amivantamab, carboplatin and pembrolizumab versus KEYNOTE-048 standard-of-care chemotherapy (platin/5-FU) plus pembrolizumab that will open soon.
With grateful acknowledgement to all the patients and their families and to the superb team at Johnson & Johnson.
More posts featuring Kevin Harrington on OncoDaily.